[Cetuximah given in combination for patients with colorectal cancer]

Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)
Record ID 32013000047
Authors' recommendations: Colorectal cancer is the third most common cancer in Denmark after breast and lung cancer and the incidence is increasing. A HTA-report concludes that the effect of Cetuximah are: - Cetuximab given in combination with irinocetan, even where another irinotecan containing regimen has failed - The appropriate patient population is approximately 150 patients - Has not been demonstrated significantly longer survival - Side effecsts may occur in the form of acne-like rash and shortness of breath - Treatment can lead to capacity challenges for the treating hospitals increased waiting times for cancer treatment generally - The total annual cost is approximately 263,000 DKKR per patients - With 150 patients, total annual costs will be almost 40 million Euro
Project Status: Completed
Year Published: 2006
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Denmark
MeSH Terms
  • Antibodies, Monoclonal
Organisation Name: Danish Centre for Evaluation and Health Technology Assessment
Contact Address: National Board of Health, PO Box 1881, Islands Brygge 67, DK-2300 Copenhagen S, Denmark. Tel: 45 72 22 74 48; Fax: 45 72 22 74 07/67
Contact Name: dacehta@sst.dk
Contact Email: dacehta@sst.dk
Copyright: Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.